Clinical Trial Update: Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 dose-escalation trial evaluating the safety and antiviral activity of Val-mCyd in adults with chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Val-mCyd (Val-mCyd)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Hepatitis C | Phase 1, Phase 2 | Status: COMPLETED